Diarrhoea Predominant Irritable Bowel Syndrome Completed Phase 3 Trials for Ibodutant (DB12042)

Also known as: Diarrhea-predominant Irritable Bowel Syndrome / IBS, Diarrhea Predominant / Irritable Bowel Syndrome With Diarrhea / Diarrhea Predominant Irritable Bowel Syndrome / Diarrhea- Predominant Irritable Bowel Syndrome / Diarrhea Dominant Irritable Bowel Syndrome / Irritable bowel syndrome with diarrhea (disorder) / Irritable bowel syndrome without diarrhea / Irritable colon / Colitis mucous / Mucous colitis / Colon spastic / Spastic colon / Irritable colon syndrome / Functional bowel syndrome / Irritable bowel / Irritable bowel syndrome / Irritable colon (disorder)

IndicationStatusPhase
DBCOND0075933 (Diarrhoea Predominant Irritable Bowel Syndrome)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT0210719612-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)Treatment